Evidence map›Paper›PMID 39133175›Full record

ReviewEndocrine-related cancer2024

SDHA-related phaeochromocytoma and paraganglioma: review and clinical management.

Adam I Kaplan, Trisha Dwight, Catherine Luxford, Diana E Benn, Roderick J Clifton-Bligh

Abstract readReview
In one paragraph

Review in Endocrine-related cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Journal of the Endocrine Society · 2026
    Article
  3. Article
  4. Tumor risks and surveillance outcomes inEndocrine oncology (Bristol, England) · 2026
    Article
  5. The evolving roles of pathologists in paragangliomas and pheochromocytomas.Virchows Archiv : an international journal of pathology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Adam I KaplanKolling Institute of Medical Research, The University of Sydney, Sydney, Australia.ORCID 0000-0001-5824-2991
Trisha DwightCancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital, Sydney, Australia.
Catherine LuxfordCancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital, Sydney, Australia.
Diana E BennCancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital, Sydney, Australia.
Roderick J Clifton-BlighDepartment of Endocrinology, Royal North Shore Hospital, Sydney, Australia.ORCID 0000-0002-1545-0368

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phaeochromocytomas and paragangliomas (collectively termed PPGL) are rare yet highly heritable neuroendocrine tumours, with over one-third of cases associated with germline pathogenic variants (PVs) in numerous genes. PVs in the succinate dehydrogenase subunit-A gene (SDHA) were initially implicated in hereditary PPGL in 2010, and SDHA has since become an important susceptibility gene accounting for up to 2.8% of cases. However, it remains poorly understood, particularly regarding the clinical nature of SDHA PPGL, rates of recurrence and metastasis, and the nature of metastatic disease. We present a narrative review of SDHA-related PPGL, covering pathophysiology, relevance to current clinical practice, and considerations for clinical genetics. We analyse a pool of 107 previously reported cases of SDHA-associated PPGL to highlight the spectrum of SDHA-related PPGL. Our analysis demonstrates that SDHA PPGL occurs across a wide age range (11-81 years) and affects men and women equally. SDHA PPGL typically presents as single tumours (91%), usually occurring in the head and neck (46%) or abdomen (43%, including 15% with phaeochromocytomas). Metastatic disease was reported in 25.5% of cases, with bone (82%) and lymph nodes (71%) being the most common sites of metastasis, often identified many years after the initial diagnosis. A family history of SDHA-related neoplasia was rare, reported in only 4% of cases. Understanding the clinical nature and risks associated with SDHA PVs is essential for facilitating the optimal management of patients and their families.

Indexed as

Adrenal Gland NeoplasmsParagangliomaPheochromocytomaAdolescentAdultAgedAged, 80 and overChildElectron Transport Complex IIFemaleHumansMaleMiddle AgedYoung AdultElectron Transport Complex IISDHA protein, humanhereditaryneoplastic syndromesparagangliomapathogenic variantphaeochromocytomapseudohypoxiaSDHAsuccinate dehydrogenase subunit-A

Identifiers

PMID39133175
PMCPMC11466202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.